EP0371636A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Improved affinity supports for hemoperfusion
Assignee: Chembiomed Ltd
•
Filing: 1989-11-08
•
Granted: —
•
Expires: 2009-11-08
Abstract
Abstract A method of coating chromatographic particulate supports to provide a biocompatible outer layer of synthetic membrane-type film which prevents the release of fines but permits the adsorption of components to an affinity ligand is described. The matrix is provided with a membrane-type coating, which prevents leaching of fines, with a pore size of at least 20 angstroms. The coating is applied to a solid particulate under conditions where an integral membrane coat will be formed. It may also be necessary to control the size and number of pores of the membranes by treating a suspension of the solid support in a solvent which contains 0.1-1% of the support weight of a biocompatible polymer along with 0.5-5% of the weight of said polymer of a dissolved compatible pore-controlling component. The solvent is then removed from the suspension and the membrane-coated material used in extracorporeal treatment of body fluids or in other chomatographic techniques. The coating process can be conducted before or after the particulate support is functionalized and/or derivatized.
Inventors
- 👤 Abdul M. Mazid
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 22:19
CPC Classifications
B; B01; B01J; B01J20/00; B01J20/30; B01J20/32; B01J20/3231; B01J20/3242; B01J20/3268; B01J20/327; A; A61; A61M; A61M1/00; A61M1/36; A61M1/3679; B01J20/281; B01J20/286; B01J20/3202; B01J20/3204; B01J20/3214; B01J20/3217; B01J20/3219; B01J20/3244; B01J20/3246; B01J20/3248; B01J20/3272; B01J20/3274; G; G01; G01N; G01N30/00; G01N30/02; G01N30/50; G01N30/52; G01N2030/524; G01N2030/525; G01N30/56; G01N2030/567; G01N30/88; G01N2030/8809; G01N2030/8813; G01N2030/8822
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
81 words
An affinity matrix suitable for extracorporeal perfusion of a body fluid for the selective removal of specific components or for chromatography which comprises: (a) a solid, particulate support derivatized to a specific affinity ligand, wherein said derivatized support is (b) coated with a biocompatible polymer, wherein the polymer coating is an integral membrane-type coating, and wherein the membrane coating has a pore size of at least 20 angstroms, and wherein said coating prevents the leaching of fine particles from the matrix.
Claim 2
Dependent Claim
81 words
An affinity matrix suitable for extracorporeal perfusion of a body fluid for the selective removal of specific components or for chromatography which comprises: (a) a solid, particulate support derivatized to a specific affinity ligand, wherein said derivatized support is (b) coated with a biocompatible polymer, wherein the polymer coating is an integral membrane-type coating, and wherein the membrane coating has a pore size of at least 20 angstroms, and wherein said coating prevents the leaching of fine particles from the matrix.
Claim 3
Dependent Claim
33 words
The matrix of claim 1 wherein the support is an inert inorganic particulate selected from the group consisting of synthetic, mineral or biogenic silicates, and wherein the affinity ligand is a carbohydrate moiety.
Claim 4
Dependent Claim
17 words
The matrix of claim 2 wherein the carbohydrate moiety is A trisaccharide (ATS) or B trisaccharide (BTS).
Claim 5
Dependent Claim
26 words
The matrix of any one of the preceding claims wherein the affinity ligand is conjugated to the support through a linker arm or through a carrier.
Claim 6
Dependent Claim
24 words
The matrix of any one of the preceding claims wherein the polymer coating is selected from polystyrene, polysulfone, polyether urethane, polydimethylsiloxane, PSMA and BSA.
Claim 7
Independent Claim
86 words
A method to coat a particulate support with a biocompatible membrane-type coating of pore size at least 20 angstoms, wherein the coating prevents the leaching of fine particles from the matrix, which method comprises: preparing a suspension of the particulate support, wherein said support is underivatized, functionalized, or derivatized with an affinity ligand in a solvent containing dissolved biocompatible polymer in an amount 0.1-1% of the weight of the support; and removing the solvent from the suspension, under conditions which result in a thin, integral membrane.
Claim 8
Independent Claim
86 words
A method to coat a particulate support with a biocompatible membrane-type coating of pore size at least 20 angstoms, wherein the coating prevents the leaching of fine particles from the matrix, which method comprises: preparing a suspension of the particulate support, wherein said support is underivatized, functionalized, or derivatized with an affinity ligand in a solvent containing dissolved biocompatible polymer in an amount 0.1-1% of the weight of the support; and removing the solvent from the suspension, under conditions which result in a thin, integral membrane.
Claim 9
Dependent Claim
39 words
The method of claim 6 wherein the matrix is derivatized with an affinity ligand optionally conjugated to the support through a linker arm or through a carrier, and wherein the support is selected from synthetic, mineral or biogenic silicates.
Claim 10
Independent Claim
113 words
A method to coat a particulate support with a biocompatible membrane-type coating of pore size at least 20 angstroms, wherein the coating prevents the leaching of fine particles from the matrix, which method comprises: preparing a suspension of the particulate support, wherein said support is underivatized, functionalized, or derivatized with an affinity ligand, in a solvent containing dissolved biocompatible polymer in an amount of 0.1-1% of the weight of the support, said solvent further containing a dissolved compatible pore-controlling component in an amount 0.5-5% of the weight of said polymer; removing the solvent from the suspension; and removing the pore-controlling component from the coating, under conditions which result in a thin, integral membrane.
Claim 11
Independent Claim
113 words
A method to coat a particulate support with a biocompatible membrane-type coating of pore size at least 20 angstroms, wherein the coating prevents the leaching of fine particles from the matrix, which method comprises: preparing a suspension of the particulate support, wherein said support is underivatized, functionalized, or derivatized with an affinity ligand, in a solvent containing dissolved biocompatible polymer in an amount of 0.1-1% of the weight of the support, said solvent further containing a dissolved compatible pore-controlling component in an amount 0.5-5% of the weight of said polymer; removing the solvent from the suspension; and removing the pore-controlling component from the coating, under conditions which result in a thin, integral membrane.
Claim 12
Dependent Claim
39 words
The method of claim 8 wherein the matrix is derivatized with an affinity ligand optionally conjugated to the support through a linker arm or through a carrier, and wherein the support is selected from synthetic, mineral or biogenic silicates.
Claim 13
Dependent Claim
26 words
The method of claim 8 or 9 wherein the biocompatible polymer is a hydrophobic polymer selected from the group consisting of polystyrene, PDMS, PEU and polysulfone.
Claim 14
Independent Claim
20 words
The method of any one of claims 8 to 10 wherein the pore-controlling component is selected from PEG and PVP.
Claim 15
Independent Claim
26 words
The method of any one of claims 8 to 11 wherein the solvent is selected from dichloromethane, chloroform, dichloroethylene, TCE, DMF, acetone/water, formic acid and EtOH.
Claim 16
Independent Claim
39 words
An apparatus of extracorporeal treatment of body fluids which comprises a cartridge loaded with a matrix of any one of claims 1 to 5 or a matrix obtained by the method of any one of claims 6 to 12.
Claim 17
Independent Claim
74 words
A method to conduct extracorporeal perfusion which comprises passing a body fluid from a subject through an affinity matrix which comprises: (i) a solid, particulate support derivatized to a specific affinity ligand, wherein said derivatized support is (ii) coated with a biocompatible polymer, wherein the polymer coating is an integral membrane-type coating having a pore size of at least 20 angstroms and wherein the coating prevents the leaching of fine particles from the matrix.
Claim 18
Independent Claim
74 words
A method to conduct extracorporeal perfusion which comprises passing a body fluid from a subject through an affinity matrix which comprises: (i) a solid, particulate support derivatized to a specific affinity ligand, wherein said derivatized support is (ii) coated with a biocompatible polymer, wherein the polymer coating is an integral membrane-type coating having a pore size of at least 20 angstroms and wherein the coating prevents the leaching of fine particles from the matrix.
Claim 19
Dependent Claim
52 words
A matrix according to any one of claims 1 to 5 or obtained by a method according to any one of claims 6 to 12 for use in a method of extracorporeal perfusion in which a body fluid is withdrawn from a subject, passed through the matrix and returned to the subject.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.